Cambridge Nutritional Sciences plc (AIM:CNSL)
London · Delayed Price · Currency is GBP · Price in GBX 2.650
0.00 (0.00%)
Oct 31, 2025, 3:27 PM GMT+1
AIM:CNSL Revenue
In the fiscal year ending March 31, 2025, Cambridge Nutritional Sciences had annual revenue of 8.33M GBP, down -14.77%. Cambridge Nutritional Sciences had revenue of 4.20M in the half year ending March 31, 2025, with 2.04% growth.
Revenue
8.33M
Revenue Growth
-14.77%
P/S Ratio
0.76
Revenue / Employee
99.17K
Employees
84
Market Cap
6.31M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 8.33M | -1.44M | -14.77% |
| Mar 31, 2024 | 9.77M | 2.23M | 29.53% |
| Mar 31, 2023 | 7.55M | -993.00K | -11.63% |
| Mar 31, 2022 | 8.54M | 1.72M | 25.28% |
| Mar 31, 2021 | 6.82M | -3.00M | -30.58% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 41.24B |
| GSK plc | 32.17B |
| Haleon | 11.02B |
| Smith & Nephew | 4.33B |
| Hikma Pharmaceuticals | 2.35B |
| ConvaTec Group | 1.72B |
| Spire Healthcare Group | 1.55B |
| Genus | 672.80M |